Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

Anika Therapeutics Inc.

The following are today's upgrades for Validea's Price/Sales Investor model based on the published strategy of Kenneth Fisher. This value strategy rewards stocks with low P/S ratios, long-term profit growth, strong free cash flow and consistent profit margins.
23ANDME HOLDING CO (MEHCQ) is a small-cap value stock in the Healthcare Facilities industry. The rating according to our strategy based on Kenneth Fisher changed from 40% to 70% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: 23andMe Holding Co. is a genetics-led consumer healthcare and biopharmaceutical company. The Company operates through two segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment comprises its Personal Genome Service (PGS), telehealth business, and research service. PGS services provide customers with a broad suite of genetic reports, including information on customersG genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Therapeutics business segment focuses on the use of genetic insights from databases of genetic and phenotypic information to develop novel therapies to improve patientsG lives. The Therapeutics segment consists of out-licensing of intellectual property associated with identified drug targets and expenses related to therapeutic product candidates.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
PRICE/SALES RATIO:
PASS
TOTAL DEBT/EQUITY RATIO:
PASS
PRICE/RESEARCH RATIO:
PASS
PRICE/SALES RATIO:
PASS
LONG-TERM EPS GROWTH RATE:
FAIL
FREE CASH PER SHARE:
FAIL
THREE YEAR AVERAGE NET PROFIT MARGIN:
FAIL
Detailed Analysis of 23ANDME HOLDING CO
MEHCQ Guru Analysis
MEHCQ Fundamental Analysis
ANIKA THERAPEUTICS INC (ANIK) is a small-cap value stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Kenneth Fisher changed from 48% to 60% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Anika Therapeutics, Inc. is engaged in the osteoarthritis pain management and regenerative solutions space focused on early intervention orthopedics. The Company is leveraging its core expertise in hyaluronic acid and implant solutions. It partners with clinicians to provide minimally invasive products that restore active living for people around the world. It is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. It is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
PRICE/SALES RATIO:
PASS
TOTAL DEBT/EQUITY RATIO:
PASS
PRICE/RESEARCH RATIO:
PASS
PRICE/SALES RATIO:
FAIL
LONG-TERM EPS GROWTH RATE:
FAIL
FREE CASH PER SHARE:
FAIL
THREE YEAR AVERAGE NET PROFIT MARGIN:
FAIL
Detailed Analysis of ANIKA THERAPEUTICS INC
ANIK Guru Analysis
ANIK Fundamental Analysis
HARMONIC INC (HLIT) is a small-cap growth stock in the Communications Equipment industry. The rating according to our strategy based on Kenneth Fisher changed from 58% to 80% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Harmonic Inc. is a provider of virtualized broadband and video delivery solutions, enables media companies and service providers to deliver video streaming and broadcast services to consumers globally. It provides broadcast and streaming video services to consumer devices, including televisions, personal computers, laptops, tablets and smartphones. The Company operates through two segments: Video and Broadband. Its Broadband segment provides broadband access solutions and related services, including its cOS software-based broadband access solution, to broadband operators globally. Its Video segment provides video processing, production and playout solutions and services worldwide to broadband operators and satellite and telco Pay-TV service providers, and to broadcast and media companies, including streaming media companies. Its video business infrastructure solutions are delivered either through shipment of its products, software licenses or as software-as-a-service subscriptions.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
PRICE/SALES RATIO:
PASS
TOTAL DEBT/EQUITY RATIO:
PASS
PRICE/RESEARCH RATIO:
PASS
PRICE/SALES RATIO:
FAIL
LONG-TERM EPS GROWTH RATE:
FAIL
FREE CASH PER SHARE:
PASS
THREE YEAR AVERAGE NET PROFIT MARGIN:
PASS
Detailed Analysis of HARMONIC INC
HLIT Guru Analysis
HLIT Fundamental Analysis
TILE SHOP HOLDINGS INC (TTSH) is a small-cap growth stock in the Constr. - Supplies & Fixtures industry. The rating according to our strategy based on Kenneth Fisher changed from 50% to 80% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Tile Shop Holdings, Inc. is a specialty retailer of natural stone and man-made tiles, setting and maintenance materials, and related accessories in the United States. The Company offers an assortment of natural stone and man-made tile products. Its natural stone products include marble, travertine, granite, quartz, sandstone, slate, and onyx tiles. The Company's man-made products include ceramic, porcelain, glass, cement, wood look, metal and luxury vinyl tile. The CompanyGs assortment of accessories, including mosaics, pencils, listellos, and other products. It also offers a range of setting and maintenance materials, such as thinset, grout, sealers, and accessories, including installation tools, shower and bath shelves, drains, and similar products. The Company also offers customers delivery service through third-party freight providers. The Company sells its products under brand names, including Superior Adhesives & Chemicals, Superior Tools & Supplies, Rush River, and Fired Earth.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
PRICE/SALES RATIO:
PASS
TOTAL DEBT/EQUITY RATIO:
PASS
PRICE/RESEARCH RATIO:
PASS
PRICE/SALES RATIO:
PASS
LONG-TERM EPS GROWTH RATE:
FAIL
FREE CASH PER SHARE:
PASS
THREE YEAR AVERAGE NET PROFIT MARGIN:
FAIL
Detailed Analysis of TILE SHOP HOLDINGS INC
TTSH Guru Analysis
TTSH Fundamental Analysis
Kenneth Fisher Portfolio
About Kenneth Fisher: The son of Philip Fisher, who is considered the "Father of Growth Investing", Kenneth Fisher is a money manager, bestselling author, and longtime Forbes columnist. The younger Fisher wowed Wall Street in the mid-1980s when his book Super Stocks first popularized the idea of using the price/sales ratio (PSR) as a means of identifying attractive stocks. According to his alma mater, Humboldt State University, Fisher is also one of the world's foremost experts on 19th century logging. Appropriately, Fisher's firm, Fisher Investments, is located in a lush forest preserve in Woodside, California, where the contrarian-minded Fisher says he and his employees can get away from Wall Street groupthink.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Validea Kenneth Fisher Strategy Daily Upgrade Report - 6/14/2025

The following are today's upgrades for Validea's Price/Sales Investor model based on the published strategy of Kenneth Fisher. This value strategy rewards stocks with low P/S ratios, long-term profit growth, strong free cash flow and consistent profit margins.
ANIKA THERAPEUTICS INC (ANIK) is a small-cap value stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Kenneth Fisher changed from 48% to 60% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Anika Therapeutics, Inc. is engaged in the osteoarthritis pain management and regenerative solutions space focused on early intervention orthopedics. The Company is leveraging its core expertise in hyaluronic acid and implant solutions. It partners with clinicians to provide minimally invasive products that restore active living for people around the world. It is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. It is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
Detailed Analysis of ANIKA THERAPEUTICS INC
ANIK Guru Analysis
ANIK Fundamental Analysis
Kenneth Fisher Portfolio
About Kenneth Fisher: The son of Philip Fisher, who is considered the "Father of Growth Investing", Kenneth Fisher is a money manager, bestselling author, and longtime Forbes columnist. The younger Fisher wowed Wall Street in the mid-1980s when his book Super Stocks first popularized the idea of using the price/sales ratio (PSR) as a means of identifying attractive stocks. According to his alma mater, Humboldt State University, Fisher is also one of the world's foremost experts on 19th century logging. Appropriately, Fisher's firm, Fisher Investments, is located in a lush forest preserve in Woodside, California, where the contrarian-minded Fisher says he and his employees can get away from Wall Street groupthink.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Validea Kenneth Fisher Strategy Daily Upgrade Report - 5/28/2025

The following are today's upgrades for Validea's Price/Sales Investor model based on the published strategy of Kenneth Fisher. This value strategy rewards stocks with low P/S ratios, long-term profit growth, strong free cash flow and consistent profit margins.
TUTOR PERINI CORP (TPC) is a small-cap growth stock in the Construction Services industry. The rating according to our strategy based on Kenneth Fisher changed from 50% to 80% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Tutor Perini Corporation is a civil, building and specialty construction company offering diversified general contracting and design-build services to private customers and public agencies throughout the world. Its Civil segment specializes in public works construction and the replacement and reconstruction of infrastructure. The contracting services provided by the Civil segment include construction and rehabilitation of highways, bridges, tunnels, mass-transit systems, and others. Its Building segment is engaged in providing services for private and public works customers in several specialized building markets, including hospitality and gaming, transportation, commercial offices, and government facilities, among others. Its Specialty Contractors segment specializes in electrical, mechanical, plumbing, HVAC and fire protection systems for a full range of civil and building construction projects in the industrial, commercial, hospitality and gaming, and mass-transit end markets.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
PRICE/SALES RATIO:
PASS
TOTAL DEBT/EQUITY RATIO:
PASS
PRICE/RESEARCH RATIO:
PASS
PRICE/SALES RATIO:
PASS
LONG-TERM EPS GROWTH RATE:
FAIL
FREE CASH PER SHARE:
PASS
THREE YEAR AVERAGE NET PROFIT MARGIN:
FAIL
Detailed Analysis of TUTOR PERINI CORP
TPC Guru Analysis
TPC Fundamental Analysis
QUANTERIX CORP (QTRX) is a small-cap growth stock in the Scientific & Technical Instr. industry. The rating according to our strategy based on Kenneth Fisher changed from 48% to 60% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Quanterix Corporation is a life sciences company. The Company develops and commercializes ultra-sensitive digital immunoassay platforms that advance life sciences research and diagnostics. Its platforms are based on its proprietary digital Simoa detection technology. Its Simoa bead-based and planar array platforms enable customers to detect protein biomarkers in low concentrations in blood, serum, and other fluids. The Company's Simoa technology is based on traditional enzyme-linked immunosorbent assay (ELISA) technology. Its products include HD-X, SR-X, SP-X, Simoa assays and consumables, Nova Beads, and neurofilament light chain (NfL) antibodies and NfL ELISA kits. It also offers contract research services for customers and laboratory developed test services through its Accelerator Laboratory, which provides customers with access to Simoa technology and supports multiple projects and services, including sample testing, homebrew assay development and custom assay development.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
PRICE/SALES RATIO:
PASS
TOTAL DEBT/EQUITY RATIO:
PASS
PRICE/RESEARCH RATIO:
PASS
PRICE/SALES RATIO:
FAIL
LONG-TERM EPS GROWTH RATE:
FAIL
FREE CASH PER SHARE:
FAIL
THREE YEAR AVERAGE NET PROFIT MARGIN:
FAIL
Detailed Analysis of QUANTERIX CORP
QTRX Guru Analysis
QTRX Fundamental Analysis
NERDY INC (NRDY) is a small-cap growth stock in the Business Services industry. The rating according to our strategy based on Kenneth Fisher changed from 48% to 60% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Nerdy Inc. operates a platform for live online learning. The CompanyGs platform leverages technology, including artificial intelligence, to connect students, users, parents, guardians, and purchasers of all ages to tutors, instructors, subject matter experts, educators, and other professionals. Its comprehensive learning destination provides learning experiences across numerous subjects and multiple formats, including learning memberships, one-on-one instruction, small group tutoring, large format classes, tutor chat, essay review, adaptive assessments, and self-study tools. Its flagship business, Varsity Tutors LLC (Varsity Tutors), is a platform for live online tutoring and classes. Its solutions are available directly to students and consumers, as well as through schools and other institutions. Its offerings include Varsity Tutors for Schools, a product suite that leverages its platform capabilities to offer high dosage tutoring and its online learning solutions to institutions.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
PRICE/SALES RATIO:
PASS
TOTAL DEBT/EQUITY RATIO:
PASS
PRICE/RESEARCH RATIO:
PASS
PRICE/SALES RATIO:
FAIL
LONG-TERM EPS GROWTH RATE:
FAIL
FREE CASH PER SHARE:
FAIL
THREE YEAR AVERAGE NET PROFIT MARGIN:
FAIL
Detailed Analysis of NERDY INC
NRDY Guru Analysis
NRDY Fundamental Analysis
ANIKA THERAPEUTICS INC (ANIK) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Kenneth Fisher changed from 48% to 60% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Anika Therapeutics, Inc. is engaged in the osteoarthritis pain management and regenerative solutions space focused on early intervention orthopedics. The Company is leveraging its core expertise in hyaluronic acid and implant solutions. It partners with clinicians to provide minimally invasive products that restore active living for people around the world. It is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. It is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
PRICE/SALES RATIO:
PASS
TOTAL DEBT/EQUITY RATIO:
PASS
PRICE/RESEARCH RATIO:
PASS
PRICE/SALES RATIO:
FAIL
LONG-TERM EPS GROWTH RATE:
FAIL
FREE CASH PER SHARE:
FAIL
THREE YEAR AVERAGE NET PROFIT MARGIN:
FAIL
Detailed Analysis of ANIKA THERAPEUTICS INC
ANIK Guru Analysis
ANIK Fundamental Analysis
Kenneth Fisher Portfolio
About Kenneth Fisher: The son of Philip Fisher, who is considered the "Father of Growth Investing", Kenneth Fisher is a money manager, bestselling author, and longtime Forbes columnist. The younger Fisher wowed Wall Street in the mid-1980s when his book Super Stocks first popularized the idea of using the price/sales ratio (PSR) as a means of identifying attractive stocks. According to his alma mater, Humboldt State University, Fisher is also one of the world's foremost experts on 19th century logging. Appropriately, Fisher's firm, Fisher Investments, is located in a lush forest preserve in Woodside, California, where the contrarian-minded Fisher says he and his employees can get away from Wall Street groupthink.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Validea Kenneth Fisher Strategy Daily Upgrade Report - 5/10/2025

Here are three stocks added to the Zacks Rank #5 (Strong Sell) List today:
A-Mark Precious Metals, Inc. AMRK is a precious metals trading company. The Zacks Consensus Estimate for its current year earnings has been revised 17.5% downward over the last 60 days.
Anika Therapeutics, Inc. ANIK is a joint preservation company. The Zacks Consensus Estimate for its current year earnings has been revised 82.8% downward over the last 60 days.
Alamo Group Inc. ALG is a vegetation management and maintenance equipment company.The Zacks Consensus Estimate for its current year earnings has been revised 6.8% downward over the last 60 days.
View the entire Zacks Rank #5 List.
Free Report: 5 Clean Energy Stocks with Massive Upside
Energy is the backbone of our economy. It’s a multi-trillion dollar industry that has created some of the world’s largest and most profitable companies.
Now state-of-the-art technology is paving the way for clean energy sources to overtake “old-fashioned” fossil fuels. Trillions of dollars are already pouring into clean energy initiatives, from solar power to hydrogen fuel cells.
Emerging leaders from this space could be some of the most exciting stocks in your portfolio.
Download Nuclear to Solar: 5 Stocks Powering the Future to see Zacks’ top picks free today.
Want the latest recommendations from Zacks Investment Research? Today, you can download 5 Stocks Set to Double. Click to get this free report
Alamo Group, Inc. (ALG) : Free Stock Analysis Report
Anika Therapeutics Inc. (ANIK) : Free Stock Analysis Report
A-Mark Precious Metals, Inc. (AMRK) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

New Strong Sell Stocks for November 11th

The following are today's upgrades for Validea's Price/Sales Investor model based on the published strategy of Kenneth Fisher. This value strategy rewards stocks with low P/S ratios, long-term profit growth, strong free cash flow and consistent profit margins.
LUCKIN COFFEE INC - ADR (LKNCY) is a mid-cap growth stock in the Retail (Grocery) industry. The rating according to our strategy based on Kenneth Fisher changed from 58% to 80% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: LUCKIN COFFEE INC. is a China-based holding company mainly engaged in coffee retail business. The Company applies new retail models for coffee sales and services. The Company operates primarily through mobile apps and pick-up stores. The Company's products mainly include freshly brewed drinks, juices and light meals. The Company's main brand is Luckin Coffee.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
Detailed Analysis of LUCKIN COFFEE INC - ADR
LKNCY Guru Analysis
LKNCY Fundamental Analysis
NEWPARK RESOURCES INC (NR) is a small-cap growth stock in the Oil Well Services & Equipment industry. The rating according to our strategy based on Kenneth Fisher changed from 50% to 80% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Newpark Resources, Inc. is a geographically diversified supplier providing products, as well as rentals and services to customers across multiple industries. The Company manufactures, sells, and rents sustainable composite matting products, along with a full suite of services, including planning, logistics, and remediation. The Company's segment is Industrial Solutions. The Industrial Solutions segment provides temporary worksite access solutions, including the rental of its recyclable composite matting systems, along with related site construction and services to customers in various markets including power transmission, oil and natural gas exploration and production (E&P), pipeline, renewable energy, petrochemical, construction and other industries, primarily in the United States and United Kingdom. It also sells its manufactured recyclable composite mats to customers around the world, with power transmission being the primary end-market.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
Detailed Analysis of NEWPARK RESOURCES INC
ANIKA THERAPEUTICS INC (ANIK) is a small-cap growth stock in the Medical Equipment & Supplies industry. The rating according to our strategy based on Kenneth Fisher changed from 48% to 60% based on the firm’s underlying fundamentals and the stock’s valuation. A score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.
Company Description: Anika Therapeutics, Inc. is a joint preservation company focused on developing, manufacturing, and commercializing products based on hyaluronic acid (HA) technology platform. The OA Pain Management product family consists of Monovisc and Orthovisc that provides pain relief from osteoarthritis conditions and Cingal consisting of its cross-linked HA material combined with a fast-acting steroid. Its Joint Preservation and Restoration product family consists of its portfolio of orthopedic regenerative solutions products: Integrity, Tactoset, and Hyalofast; its line of sports medicine solutions repairs and reconstructs damaged ligaments and tendons, and its Arthrosurface portfolio of bone preserving joint technologies, including partial joint replacement, joint resurfacing, and minimally invasive and bone sparing implants. Its Non-Orthopedic product family provides orthopedic applications, including adhesion barrier product, advanced wound care products, and ear, nose and throat products.
The following table summarizes whether the stock meets each of this strategy's tests. Not all criteria in the below table receive equal weighting or are independent, but the table provides a brief overview of the strong and weak points of the security in the context of the strategy's criteria.
Detailed Analysis of ANIKA THERAPEUTICS INC
ANIK Guru Analysis
ANIK Fundamental Analysis
Kenneth Fisher Portfolio
About Kenneth Fisher: The son of Philip Fisher, who is considered the "Father of Growth Investing", Kenneth Fisher is a money manager, bestselling author, and longtime Forbes columnist. The younger Fisher wowed Wall Street in the mid-1980s when his book Super Stocks first popularized the idea of using the price/sales ratio (PSR) as a means of identifying attractive stocks. According to his alma mater, Humboldt State University, Fisher is also one of the world's foremost experts on 19th century logging. Appropriately, Fisher's firm, Fisher Investments, is located in a lush forest preserve in Woodside, California, where the contrarian-minded Fisher says he and his employees can get away from Wall Street groupthink.
About Validea: Validea is aninvestment researchservice that follows the published strategies of investment legends. Validea offers both stock analysis and model portfolios based on gurus who have outperformed the market over the long-term, including Warren Buffett, Benjamin Graham, Peter Lynch and Martin Zweig. For more information about Validea, click here
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Validea Kenneth Fisher Strategy Daily Upgrade Report - 11/2/2024

The following companies are expected to report earnings after hours on 03/13/2024. Visit our Earnings Calendar for a full list of expected earnings releases.
Lennar Corporation (LEN)is reporting for the quarter ending February 29, 2024. The building (residential/commercial) company's consensus earnings per share forecast from the 9 analysts that follow the stock is $2.21. This value represents a 4.25% increase compared to the same quarter last year. In the past year LEN and beat the expectations the other two quarters. Zacks Investment Research reports that the 2024 Price to Earnings ratio for LEN is 11.56 vs. an industry ratio of 10.30, implying that they will have a higher earnings growth than their competitors in the same industry.
UiPath, Inc. (PATH)is reporting for the quarter ending January 31, 2024. The technology services company's consensus earnings per share forecast from the 3 analysts that follow the stock is $-0.04. This value represents a 33.33% decrease compared to the same quarter last year. In the past year PATH and beat the expectations the other two quarters. Zacks Investment Research reports that the 2024 Price to Earnings ratio for PATH is -112.00 vs. an industry ratio of -17.50.
SentinelOne, Inc. (S)is reporting for the quarter ending January 31, 2024. The information technology services company's consensus earnings per share forecast from the 10 analysts that follow the stock is $-0.23. This value represents a 23.33% increase compared to the same quarter last year. S missed the consensus earnings per share in the 2nd calendar quarter of 2023 by -6.06%. Zacks Investment Research reports that the 2024 Price to Earnings ratio for S is -26.62 vs. an industry ratio of -4.50.
MorphoSys AG (MOR)is reporting for the quarter ending December 31, 2023. The biomedical (gene) company's consensus earnings per share forecast from the 1 analyst that follows the stock is $-1.06. This value represents a 146.49% decrease compared to the same quarter last year. In the past year MORThe days to cover, as reported in the 2/29/2024 short interest update, increased 265.25% from previous report on 2/15/2024. Zacks Investment Research reports that the 2023 Price to Earnings ratio for MOR is -7.21 vs. an industry ratio of 0.40.
Navigator Holdings Ltd. (NVGS)is reporting for the quarter ending December 31, 2023. The shipping company's consensus earnings per share forecast from the 2 analysts that follow the stock is $0.31. This value represents a 121.43% increase compared to the same quarter last year. NVGS missed the consensus earnings per share in the 4th calendar quarter of 2022 by -30%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for NVGS is 13.55 vs. an industry ratio of 6.90, implying that they will have a higher earnings growth than their competitors in the same industry.
North American Construction Group Ltd. (NOA)is reporting for the quarter ending December 31, 2023. The building company's consensus earnings per share forecast from the 3 analysts that follow the stock is $0.59. This value represents a 27.16% decrease compared to the same quarter last year. In the past year NOA and beat the expectations the other three quarters. Zacks Investment Research reports that the 2023 Price to Earnings ratio for NOA is 14.98 vs. an industry ratio of 21.20.
NextNav Inc. (NN)is reporting for the quarter ending December 31, 2023. The technology services company's consensus earnings per share forecast from the 1 analyst that follows the stock is $-0.14. This value represents a 7.69% decrease compared to the same quarter last year. NN missed the consensus earnings per share in the 2nd calendar quarter of 2023 by -7.14%. The "days to cover" for this stock exceeds 14 days. Zacks Investment Research reports that the 2023 Price to Earnings ratio for NN is -7.94 vs. an industry ratio of -17.50, implying that they will have a higher earnings growth than their competitors in the same industry.
VAALCO Energy, Inc. (EGY)is reporting for the quarter ending December 31, 2023. The international company's consensus earnings per share forecast from the 1 analyst that follows the stock is $0.15. This value represents a 21.05% decrease compared to the same quarter last year. The last two quarters EGY had negative earnings surprises; the latest report they missed by -8.33%. Zacks Investment Research reports that the 2023 Price to Earnings ratio for EGY is 10.85 vs. an industry ratio of 4.70, implying that they will have a higher earnings growth than their competitors in the same industry.
Pangaea Logistics Solutions Ltd. (PANL)is reporting for the quarter ending December 31, 2023. The shipping company's consensus earnings per share forecast from the 1 analyst that follows the stock is $0.44. This value represents a 37.50% increase compared to the same quarter last year. Zacks Investment Research reports that the 2023 Price to Earnings ratio for PANL is 8.62 vs. an industry ratio of 6.90, implying that they will have a higher earnings growth than their competitors in the same industry.
Anika Therapeutics Inc. (ANIK)is reporting for the quarter ending December 31, 2023. The biomedical (gene) company's consensus earnings per share forecast from the 1 analyst that follows the stock is $-0.15. This value represents a 28.57% increase compared to the same quarter last year. Zacks Investment Research reports that the 2023 Price to Earnings ratio for ANIK is -57.31 vs. an industry ratio of 0.40.
Hallador Energy Company (HNRG)is reporting for the quarter ending December 31, 2023. The coal company's consensus earnings per share forecast from the 1 analyst that follows the stock is $0.29. This value represents a 65.06% decrease compared to the same quarter last year. In the past year HNRG and beat the expectations the other three quarters. Zacks Investment Research reports that the Price to Earnings ratio for HNRG is 0.00 vs. an industry ratio of 7.10.
Coherus BioSciences, Inc. (CHRS)is reporting for the quarter ending December 31, 2023. The biomedical (gene) company's consensus earnings per share forecast from the 3 analysts that follow the stock is $-0.33. This value represents a 56.58% increase compared to the same quarter last year. CHRS missed the consensus earnings per share in the 1st calendar quarter of 2023 by -15.58%. The "days to cover" for this stock exceeds 10 days. Zacks Investment Research reports that the 2023 Price to Earnings ratio for CHRS is -1.03 vs. an industry ratio of 0.40.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

After-Hours Earnings Report for March 13, 2024 : LEN, PATH, S, MOR, NVGS, NOA, NN, EGY, PANL, ANIK, HNRG, CHRS

March 7 (Reuters) - Activist investor Caligan Partners has disclosed a 9.7% stake in Anika Therapeutics ANIK.O and nominated two director candidates to the drugmaker's board.
Caligan nominated David Johnson and William Jellison to the company's board, according to a regulatory filing late on Wednesday. It previously had roughly a 7% stake, a filing in September last year showed.
In the new filing, Caligan said Anika's shares "are significantly undervalued and represent a compelling investment opportunity".
Caligan, which specializes in healthcare investing, had previously urged the company to consider strategic alternatives, including a full sale, as its stock price underperformed and it faced losses at its joint preservation segment.
In April last year, Anika, which makes osteoarthritis knee pain relief injection treatments, reached a settlement with Caligan. It had then appointed former Johnson & Johnson JNJ.N executive Gary Fischetti as a director to its board.
Shares of Anika, which also makes implants that are used in soft tissue repair procedures, closed at $26.03 on Wednesday, versus the peak of $75.72 hit in 2019.
(Reporting by Manas Mishra and Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar)
((Sriparna.Roy@thomsonreuters.com))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Activist investor Caligan discloses 9.7% stake in Anika, nominates two director candidates

Guardant Health (GH) came out with a quarterly loss of $1.58 per share versus the Zacks Consensus Estimate of a loss of $0.93. This compares to loss of $1.36 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -69.89%. A quarter ago, it was expected that this provider of oncology testing services would post a loss of $0.93 per share when it actually produced a loss of $0.73, delivering a surprise of 21.51%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
Guardant Health, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $155.05 million for the quarter ended December 2023, surpassing the Zacks Consensus Estimate by 2.20%. This compares to year-ago revenues of $126.89 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Guardant Health shares have lost about 16.2% since the beginning of the year versus the S&P 500's gain of 4.4%.
What's Next for Guardant Health?
While Guardant Health has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Guardant Health: favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.87 on $151.43 million in revenues for the coming quarter and -$3.36 on $670.71 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 36% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Anika Therapeutics (ANIK), has yet to report results for the quarter ended December 2023.
This medical technology company is expected to post quarterly loss of $0.26 per share in its upcoming report, which represents a year-over-year change of +23.5%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Anika Therapeutics' revenues are expected to be $41.51 million, up 4.8% from the year-ago quarter.
Top 5 ChatGPT Stocks Revealed
Zacks Senior Stock Strategist, Kevin Cook names 5 hand-picked stocks with sky-high growth potential in a brilliant sector of Artificial Intelligence. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
Today you can invest in the wave of the future, an automation that answers follow-up questions … admits mistakes … challenges incorrect premises … rejects inappropriate requests. As one of the selected companies puts it, “Automation frees people from the mundane so they can accomplish the miraculous.”
Download Free ChatGPT Stock Report Right Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Guardant Health (GH) Reports Q4 Loss, Tops Revenue Estimates

Anika Therapeutics, Inc. (ANIK) Q3 2023 Earnings Call Transcript
Anika Therapeutics, Inc. (ANIK)
Q3 2023 Earnings Conference Call
Company Participants
Mark Namaroff - Vice President Investor Relations, ESG & Corporate Communications
Cheryl Blanchard - President & Chief Executive Officer
Mike Levitz - Executive Vice President, Chief Financial Officer & Treasurer
Conference Call Participants
Mike Petusky - Barrington Research
George Sellers - Stephens Inc
Jim Sidoti - Sidoti & Company
Presentation
Operator
Good evening, ladies and gentlemen, and welcome to Anika's Third Quarter 2023 Earnings Conference Call. All participants' will be in a listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note today's event is being recorded.
I'd now like to introduce Mark Namaroff, Vice President Investor Relations, ESG and Corporate Communications. Please proceed.
Mark Namaroff
Thank you. Good afternoon, everyone and thank you for joining us for Anika's Third Quarter Conference Call and Webcast. Our Q3 earnings press release was issued after the close of the market today and then available on our Investor Relations website located at anika.com as our supplementary PowerPoint slides that will be used for the discussion today.
With me on the call today are Dr. Cheryl Blanchard, President and Chief Executive Officer; and Mike Levitz, Executive Vice President, Chief Financial Officer and Treasurer. Please take a moment and open the slide presentation and refer to Slide number 2.
Before we begin, please understand that certain statements made during the call today constitute forward-looking statements as defined in the Securities Exchange Act of 1934. These statements are based on our current beliefs and expectations and are subject to certain risks and uncertainties. The company's actual results could differ materially from any anticipated future results performance or achievements. We make no obligation to update these statements should future financial data or events occur that differ from the forward-looking statements presented today.
Please also see our most recent SEC filings for more information about risk factors that could affect our performance. In addition, during the call, we may refer to several adjusted or non-GAAP financial measures, which include adjusted gross margin, adjusted EBITDA, adjusted net income and adjusted earnings per share, which are used in addition to results presented in accordance with GAAP financial measures.
We believe that non-GAAP measures provide an additional way of viewing aspects of our operational performance. But when considered with GAAP financial measures and the reconciliation of GAAP measures, they provide an even more complete understanding of our business. A reconciliation of these adjusted non-GAAP financial measures to the most comparable GAAP measurements are available at the end of the presentation slide deck and in our third quarter 2023 press release.
And now, I'd like to turn the call over to our President and CEO, Dr. Cheryl Blanchard. Cheryl?
Cheryl Blanchard
Thanks, Mark. Good afternoon, everyone and thanks for joining us. Please turn to Slide 3. We are pleased with our third quarter results, which underscore the strength of our strategy and reinforce our confidence in the powerful growth engine we've created. Following a period of purposeful investments to enable our transformation into the largest and highest opportunity areas of the joint preservation market, we are beginning to see the accelerated growth and momentum building across the business we've been working toward for some time.
We delivered 14% growth in Joint Preservation and Restoration in the quarter and higher-than-expected growth in OA Pain Management, which has now grown 11% year-to-date. The acceleration in Joint Preservation and Restoration is being led by our newest products X-Twist and RevoMotion, which are gaining traction and generating a lot of interest in the markets we serve. The double-digit growth in the quarter positions us well for Q4 and as we head into 2024. The continued growth in our OA pain business follows a strong second quarter led by Monovisc growth globally and double-digit Cingal growth outside the US.
Given the strong performance across our business, we are raising our revenue and EBITDA margin guidance for the year which Mike will go into in a minute. Our expanding Joint Preservation and Restoration portfolio has been key to our continued growth and we achieved a number of important milestones in the third quarter. Our RevoMotion reverse shoulder arthroplasty system had a very successful full market release in September at the OSET Annual Meeting in Boston attracting strong interest from surgeons.
We also received the final 510(k) clearance from the FDA for our Integrity Implant System and we're on track for full launch in the first quarter of 2024. As a reminder, Integrity is our truly differentiated regenerative HA-based patch system for the augmentation of rotator cuff and other tendon repairs. Our X-Twist Fixation System also achieved a significant milestone this quarter, receiving 510(k) clearance for the biocomposite version, complementing the PEEK version that was released earlier this year.
The clearance of X-Twist biocomposite now allows Anika to address the full US$600 million rotator cuff market. We are on track to launch the Biocomposite version in Q1 of 2024. We also reached a milestone in Medical Education training over 500 surgeons this year across our full Joint Preservation and Restoration portfolio.
We're pleased to see that OA Pain Management continues to outperform. This includes J&J's above-market growth and share capture as they continue to expand their number one market position in the US OA Pain Management segment.
Outside the US, Cingal has consistently delivered double-digit growth and is the next-generation non-opioid osteoarthritis pain product of choice in over 35 countries. Cingal's highly-differentiated clinical profile and its demonstrated real-world benefits have underpinned its international growth.
We continue to explore Cingal partnership opportunities in the US and select Asian countries with significant interest from several parties. We're also continuing to engage with the FDA to advance Cingal towards US regulatory approval.
As a reminder, we had a Type C Meeting with the FDA earlier this year. And we are awaiting feedback on our proposal to them on next steps to complete non-clinical work so that we can file an NDA as quickly as possible. We will continue to keep everyone updated on this process.
Our Cingal market adoption and double-digit growth outside the US reinforces, that this next-generation product would be a meaningful addition to US clinicians' arsenals to treat OA Pain with a non-opioid product.
On Slide 4, I'd like to spend a few minutes reviewing our Integrity System, which will be a key value driver for Anika and a game-changer in how surgeons augment their rotator cuff and other tendon repairs.
Integrity's key differentiating feature is the inherent structural integrity of the Hyaluronic acid-based scaffolds, compared to the current collagen patches on the market. This strength comes from its HA-based hybrid structure resulting in a patch that is over 50% stronger than the leading collagen patch in Tensile Strength, Suture Retention and Tear Resistance even when hydrated.
That provides for the ability to confidently manipulate the patch intraoperatively and strongly affix it with staple, tacks or suture during the repair. Another key value driver for Integrity is in its regenerative capacity. The hyaluronic acid scaffolds support healing through improved cell infiltration, tissue remodeling and tendon thickening.
In a head-to-head animal study the Integrity patch demonstrated about three times the regenerative capacity compared to the leading collagen patch. This data is important to both the surgeon and the patient.
The combination of Integrity's strength, increased regenerative capacity and an efficient reproducible delivery system is what is getting surgeons really excited. We are feeling a pull from surgeons excited for Integrity to launch.
We're confident that it will become the standard of care in rotator cuff augmentation and along with our recently-launched RevoMotion and X-Twist position us to drive growth for years to come.
Please turn to Slide 5. We've been investing with purpose to establish Anika, as a global leader addressing unmet needs in early intervention orthopedics. We are leveraging our core expertise in hyaluronic acid and portfolio across OA Pain Management, Regenerative, Sports Medicine and Arthrosurface Joint Solutions.
The investments we've made over the past three years are now beginning to bear fruit. In fact most of the products on this slide are either launched or are launching in the first quarter of 2024 into larger markets than Anika has entered before in our direct business, setting up 2024 as an exciting year.
In addition to those products our value-driving Cingal and Hyalofast products have now advanced and are closer than they have ever been with line of sight to US regulatory filings for both products. We expect the next-generation OA Pain market served by Cingal adds an additional $1 billion plus to our existing $1 billion market opportunity served by MONOVISC and ORTHOVISC and Cingal is perfectly positioned to win.
Hyalofast addresses the $1 billion-plus cartilage repair market with a single-stage off-the-shelf regenerative product. Now that we are fully enrolled in our pivotal trial, this breakthrough device has a well-defined pathway to launch in the US market by 2026. In short, our highly-differentiated new product pipeline is being realized....
Read the full article on Seeking Alpha
]]>
© www.conferencecalltranscripts.org 2020 | Terms of Service

Anika Therapeutics, Inc. (ANIK) Q3 2023 Earnings Call Transcript

Structure Therapeutics’ GPCR shares were up 9.1 % this week, owing to a positive announcement last week. On Sep 29, the company announced positive data from the early-stage study of its weight loss candidate, GSBR-1290.
GSBR-1290 is a highly selective oral GLP-1 receptor agonist, being evaluated in a phase Ib multiple ascending dose study (across three dose cohorts with target doses of 30mg, 60mg or 90mg) in healthy overweight or obese individuals.
GSBR-1290 was administered as a daily oral pill. Initial findings from the study showed that patients receiving 90mg dose of GSBR-1290 experienced a remarkable 5.4% reduction in their body weight, while the placebo group experienced only a 0.5% decrease in body weight throughout the 28-day treatment period.
The candidate was well tolerated and no adverse events related to discontinuation in the phase I study was observed.
The company plans to report top-line data from the type II diabetes cohort of the phase IIa study by 2023-end and from the obesity cohort in the first half of 2024. Furthermore, a phase IIb study of GSBR-1290 in type II diabetes and obesity patients is expected to be initiated by 2024.
Shares of Structure Therapeutics have risen 108.5% year to date against the industry’s 17.8% decline.
Image Source: Zacks Investment Research
GLP-1 receptor agonists stimulate insulin secretion and inhibit glucagon release from the pancreas, leading to improved blood sugar control. They also reduce appetite and slow gastric emptying, aiding in weight management.
Several other companies like the bigwig Eli Lilly LLY and Novo Nordisk NVO are developing or have developed injectable treatments for weight management.
LLY’s Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist, approved for managing blood sugar levels in adults with type II diabetes. The company is also seeking FDA’s approval for expansion of the drug indication to include obesity and weight management.
Mounjaro has shown superior weight-loss reduction in clinical studies for the obesity indication. Regulatory applications have already been filed for the drug for obesity indication in the United States and European Union.
In the United States, the FDA has assigned priority review to the regulatory filing with a decision expected by 2023-end. LLY generated sales of $1.55 billion in the first half of 2023 from Mounjaro.
Novo Nordisk’s popular GLP-1 receptor agonist, Wegovy (semaglutide – 2.5 mg), is an anti-obesity injection. Wegovy is seeing strong prescription trends and generating impressive revenues for Novo Nordisk.
In clinical studies, patients taking Wegovy have experienced an average 15% weight loss over a 68-week period. Wegovy sales were up 363% at constant exchange rate in the first half of 2023.
Structure Therapeutics Inc. Sponsored ADR Price and Consensus
Zacks Rank & Stock to Consider
Structure Therapeutics currently carries a Zacks Rank #3 (Hold).
A better-ranked stock in the same industry is Anika Therapeutics ANIK, carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here
In the past 90 days, the Zacks Consensus Estimate forAnika Therapeutics has narrowed from a loss of $1.41 per share to a loss of $1.24 for 2023. The bottom-line estimate has widened from a loss of 79 cents to a loss of 82 cents for 2024 during the same time frame. Shares of the company have lost 36.3% year to date.
ANIK’s earnings beat estimates in one of the trailing four quarters and missed the mark in the remaining three, delivering an average negative surprise of 32.12%.
Zacks Reveals ChatGPT "Sleeper" Stock
One little-known company is at the heart of an especially brilliant Artificial Intelligence sector. By 2030, the AI industry is predicted to have an internet and iPhone-scale economic impact of $15.7 Trillion.
As a service to readers, Zacks is providing a bonus report that names and explains this explosive growth stock and 4 other "must buys." Plus more.
Download Free ChatGPT Stock Report Right Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Indicator	TTM Median
P/E	0.00 23.75
Price/Sales	1.42 3.01
P/B	1.45 2.20
P/FCF	0.00 18.30

Indicator	TTM Median
ROE	0.00 25.41
ROA	0.00 6.00
ROI	0.00 9.66
Net Worth	0.16 0.20
Quick Ratio	4.54 1.71
Current Ratio	5.73 2.83

Indicator	TTM Median
Net Profit Margin	0.00 10.25
Operating Margin	0.00 14.24
Gross Margin	60.68 68.57
Return on tangible equity	0.00 53.53

Indicator	TTM Median
EPS	0.28 0.37
EPS Forecast	0.13 0.37
Revenue	26.00M 16.00M
Gross Profit	15.00M —
EBITDA	0.00 —

Anika Therapeutics Inc.

Indicators ANIK

Valuation

Debts

Efficiency

Other ratios

Revenue